These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31408695)

  • 1. Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer.
    Guo J; Wang Q; Zhang Y; Sun W; Zhang S; Li Y; Wang J; Bao Y
    Pharmacol Res; 2019 Sep; 147():104387. PubMed ID: 31408695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells: potential chemosensitizing effect.
    Rigalli JP; Scholz PN; Tocchetti GN; Ruiz ML; Weiss J
    Eur J Nutr; 2019 Feb; 58(1):139-150. PubMed ID: 29101532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
    Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
    Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
    Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
    Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
    Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
    Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)
    Chong TC; Wong ILK; Cui J; Law MC; Zhu X; Hu X; Kan JWY; Yan CSW; Chan TH; Chow LMC
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
    Jia P; Wu S; Li F; Xu Q; Wu M; Chen G; Liao G; Wang S; Zhou J; Lu Y; Ma D
    Int J Gynecol Cancer; 2005; 15(6):1042-8. PubMed ID: 16343180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
    Imai Y; Ishikawa E; Asada S; Sugimoto Y
    Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The mechanism of topotecan resistance in ovarian cancer cell line].
    Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
    Yang CH; Chen YC; Kuo ML
    Anticancer Res; 2003; 23(3B):2519-23. PubMed ID: 12894535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.